Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL

The Phase 1/2 ZUMA-6 trial evaluated the safety and efficacy of axicabtagene ciloleucel (axi-cel) in combination with the PD-L1 inhibitor atezolizumab in patients with refractory diffuse large B-cell lymphoma (DLBCL).
The combination demonstrated a manageable safety profile with no new safety signals; Grade 3 or higher cytokine release syndrome (CRS) occurred in 9% of patients, and neurologic events occurred in 32%.
Efficacy outcomes were robust, with a complete response (CR) rate of 54% and a median overall survival (OS) of 32.2 months at a median follow-up of 56.9 months.
Despite the theoretical synergy of checkpoint inhibition, the efficacy and CAR T-cell pharmacokinetics were largely consistent with historical data from axi-cel monotherapy (ZUMA-1).

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The Phase 1/2 ZUMA-6 trial evaluated the safety and efficacy of axicabtagene ciloleucel (axi-cel) in combination with the PD-L1 inhibitor atezolizumab in patients with refractory diffuse large B-cell lymphoma (DLBCL).
The combination demonstrated a manageable safety profile with no new safety signals; Grade 3 or higher cytokine release syndrome (CRS) occurred in 9% of patients, and neurologic events occurred in 32%.
Efficacy outcomes were robust, with a complete response (CR) rate of 54% and a median overall survival (OS) of 32.2 months at a median follow-up of 56.9 months.
Despite the theoretical synergy of checkpoint inhibition, the efficacy and CAR T-cell pharmacokinetics were largely consistent with historical data from axi-cel monotherapy (ZUMA-1).

Sign in free to continue reading